However, some specialists describe Benlysta?s efficacy as modest, and many believe Gazyva could offer an advancement in treating LN. While Gazyva may take time to gain market share due to Benlysta?s entrenched position and strong track record, the promising results from its Phase III trial in LN hint at its potential to outperform in key areas. Although its Phase III trial in SLE won?t conclude until late 2025, Gazyva?s impact on LN patients?particularly in improving musculoskeletal and dermatologic manifestations?could possibly become evident sooner, potentially accelerating its uptake in both LN and SLE treatment. Meanwhile, Lupkynis, a novel calcineurin inhibitor, has carved out a niche for itself in LN patients with high, persistent proteinuria. Spherix?s Patient Chart Dynamix?: LN audit (US) indicates that, compared to Benlysta and rituximab, Lupkynis is the go-to treatment for this patient subset.